JP2021534096A5 - - Google Patents
Info
- Publication number
- JP2021534096A5 JP2021534096A5 JP2021506582A JP2021506582A JP2021534096A5 JP 2021534096 A5 JP2021534096 A5 JP 2021534096A5 JP 2021506582 A JP2021506582 A JP 2021506582A JP 2021506582 A JP2021506582 A JP 2021506582A JP 2021534096 A5 JP2021534096 A5 JP 2021534096A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- chain variable
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862716113P | 2018-08-08 | 2018-08-08 | |
| US201862716106P | 2018-08-08 | 2018-08-08 | |
| US201862716109P | 2018-08-08 | 2018-08-08 | |
| US62/716,106 | 2018-08-08 | ||
| US62/716,113 | 2018-08-08 | ||
| US62/716,109 | 2018-08-08 | ||
| PCT/US2019/045723 WO2020033702A1 (en) | 2018-08-08 | 2019-08-08 | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021534096A JP2021534096A (ja) | 2021-12-09 |
| JP2021534096A5 true JP2021534096A5 (enExample) | 2022-08-15 |
Family
ID=69415684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021506582A Pending JP2021534096A (ja) | 2018-08-08 | 2019-08-08 | Ｎｋｇ２ｄ、ｃｄ１６および腫瘍関連抗原に結合するタンパク質 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210206859A1 (enExample) |
| EP (1) | EP3833686A4 (enExample) |
| JP (1) | JP2021534096A (enExample) |
| KR (1) | KR20210044237A (enExample) |
| CN (1) | CN112789291A (enExample) |
| AU (1) | AU2019319906A1 (enExample) |
| BR (1) | BR112021002278A2 (enExample) |
| CA (1) | CA3108915A1 (enExample) |
| IL (1) | IL280673A (enExample) |
| MX (1) | MX2021001510A (enExample) |
| SG (1) | SG11202101294RA (enExample) |
| WO (1) | WO2020033702A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| KR102211837B1 (ko) | 2013-01-14 | 2021-02-03 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| EP3223907A2 (en) | 2014-11-26 | 2017-10-04 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd38 |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| PE20171324A1 (es) | 2014-11-26 | 2017-09-11 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales |
| CN109715663B (zh) | 2016-06-28 | 2022-11-25 | Xencor股份有限公司 | 结合生长抑素受体2的异源二聚抗体 |
| AU2017359155A1 (en) * | 2016-11-10 | 2019-06-13 | Medimmune, Llc | Binding molecules specific for ASCT2 and uses thereof |
| AU2018219887B2 (en) | 2017-02-08 | 2024-08-15 | Dragonfly Therapeutics, LLC | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| CN110944661A (zh) | 2017-02-20 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 结合her2、nkg2d和cd16的蛋白质 |
| JP2021502100A (ja) | 2017-11-08 | 2021-01-28 | ゼンコア インコーポレイテッド | 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体 |
| BR112020015994A2 (pt) | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer |
| CA3237846A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| WO2019164930A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| CA3096052A1 (en) | 2018-04-04 | 2019-10-10 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE |
| KR102835308B1 (ko) | 2018-08-08 | 2025-07-21 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| JP7512394B2 (ja) | 2020-05-06 | 2024-07-08 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質 |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| CA3192204A1 (en) * | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
| EP4257154A4 (en) * | 2021-02-09 | 2026-04-22 | Medilink Therapeutics Suzhou Co Ltd | CONJUGATED WITH A BIOACTIVE SUBSTANCE, ITS PREPARATION PROCESS AND ITS USE |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| US11739144B2 (en) | 2021-03-09 | 2023-08-29 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and CLDN6 |
| EP4305065A1 (en) | 2021-03-10 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
| WO2022258691A1 (en) * | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| US20230151095A1 (en) * | 2021-11-12 | 2023-05-18 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and nkg2d |
| WO2023141600A2 (en) * | 2022-01-20 | 2023-07-27 | Repertoire Immune Medicines, Inc. | Silent anti-cd8 antibodies and fusion proteins |
| US12365743B2 (en) | 2022-02-23 | 2025-07-22 | Xencor, Inc. | Anti-CD28 x anti-PSMA antibodies |
| CN115960234B (zh) * | 2022-10-27 | 2023-12-29 | 合肥天港免疫药物有限公司 | 抗cd16a的抗体及其应用 |
| WO2024102636A1 (en) | 2022-11-07 | 2024-05-16 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and mica/b |
| WO2024102693A2 (en) | 2022-11-07 | 2024-05-16 | Xencor, Inc. | Il-18-fc fusion proteins |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7285269B2 (en) * | 2002-12-02 | 2007-10-23 | Amgen Fremont, Inc. | Antibodies directed to tumor necrosis factor |
| EP2542256B1 (en) * | 2010-03-04 | 2019-05-22 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| PH12012501751A1 (en) * | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| WO2012147713A1 (ja) * | 2011-04-25 | 2012-11-01 | 第一三共株式会社 | 抗ｂ７－ｈ３抗体 |
| EA035419B9 (ru) * | 2014-05-29 | 2020-08-07 | Мэкроудженикс, Инк. | Триспецифичные связывающие молекулы и способы их применения |
| CN107405399B (zh) * | 2015-01-02 | 2022-02-08 | 武田药品工业株式会社 | 针对血浆激肽释放酶和因子xii的双特异性抗体 |
| AU2016284871B2 (en) * | 2015-06-23 | 2022-09-29 | Innate Pharma | Multispecific NK engager proteins |
| WO2017165464A1 (en) * | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| GEP20227398B (en) * | 2016-04-15 | 2022-07-25 | Macrogenics Inc | Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof |
| AU2017279550A1 (en) * | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-B7-H3 antibodies and antibody drug conjugates |
| CN105906722B (zh) * | 2016-06-24 | 2020-02-07 | 安徽未名细胞治疗有限公司 | 一种Her2特异性嵌合抗原受体及其应用 |
| AU2017319519A1 (en) * | 2016-09-01 | 2019-04-18 | Immunomab, Inc. | Bispecific antibodies |
| AU2018219887B2 (en) * | 2017-02-08 | 2024-08-15 | Dragonfly Therapeutics, LLC | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| CA3237846A1 (en) * | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| BR112020015994A2 (pt) * | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer |
| EA202091977A1 (ru) * | 2018-05-28 | 2021-02-09 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения |
| US20230151095A1 (en) * | 2021-11-12 | 2023-05-18 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and nkg2d |
-
2019
- 2019-08-08 JP JP2021506582A patent/JP2021534096A/ja active Pending
- 2019-08-08 EP EP19848152.5A patent/EP3833686A4/en active Pending
- 2019-08-08 AU AU2019319906A patent/AU2019319906A1/en not_active Abandoned
- 2019-08-08 CN CN201980064178.3A patent/CN112789291A/zh active Pending
- 2019-08-08 WO PCT/US2019/045723 patent/WO2020033702A1/en not_active Ceased
- 2019-08-08 KR KR1020217006244A patent/KR20210044237A/ko not_active Ceased
- 2019-08-08 BR BR112021002278-3A patent/BR112021002278A2/pt unknown
- 2019-08-08 MX MX2021001510A patent/MX2021001510A/es unknown
- 2019-08-08 CA CA3108915A patent/CA3108915A1/en active Pending
- 2019-08-08 SG SG11202101294RA patent/SG11202101294RA/en unknown
- 2019-08-08 US US17/265,879 patent/US20210206859A1/en not_active Abandoned
-
2021
- 2021-02-05 IL IL280673A patent/IL280673A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021534096A5 (enExample) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2021533159A5 (enExample) | ||
| JP2021098733A5 (enExample) | ||
| JP2021098732A5 (enExample) | ||
| JP2021512630A5 (enExample) | ||
| JP2021533169A5 (enExample) | ||
| JP2020533311A5 (ja) | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 | |
| JP2021522162A5 (enExample) | ||
| FI3582806T3 (fi) | Her2:ta, nkg2d:tä ja cd16:ta sitovia proteiineja | |
| JP2022551969A5 (enExample) | ||
| JP2020522473A5 (enExample) | ||
| FI3749346T3 (fi) | Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät | |
| JP2023538945A5 (enExample) | ||
| JP2021514396A5 (enExample) | ||
| JP2020521448A5 (enExample) | ||
| JP2020508997A5 (enExample) | ||
| JP2024056687A5 (enExample) | ||
| RU2021110369A (ru) | Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген | |
| JP2020510422A5 (enExample) | ||
| JP2023516004A5 (enExample) | ||
| JP2018507188A5 (enExample) | ||
| JP2021523140A5 (enExample) | ||
| JP2022533538A5 (enExample) | ||
| JP2020507577A5 (enExample) |